Factors Influencing Hemoglobin Variability and Its Association With Mortality in Hemodialysis Patients

Hemodialysis-Induced Symptom Clinical Trial

Official title:

Baskent University Nephrology Department

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03454906
• Other study ID #: KA09/358
• Status: Completed
• Phase: N/A
• First received: February 2, 2018
• Last updated: February 27, 2018
• Start date: January 2009
• Est. completion date: February 2010

Study information

• Verified date: February 2018
• Source: Baskent University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to investigate the factors influencing hemoglobin variability with inflammatory and nutritional parameters and its associations with all-cause mortality among hemodialysis patients.

Description:

Fluctuation in hemoglobin levels that is known as hemoglobin variability during treatment with ESA is a well-documented phenomenon. Several factors have been found to affect hemoglobin variability, including drug related, such as pharmacokinetic parameters, patient-related differences in demographic characteristics and factors affecting clinical status, as well as clinical practice guidelines, treatment protocols and reimbursement policies. Inflammation is also an important factor associated with hemoglobin variability, and the consequences of persistent inflammatory activity are far-reaching in affected patients.

In present study, the factors influencing hemoglobin variability with inflammatory and nutritional parameters and its associations with all-cause mortality among hemodialysis patients are investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 169
• Est. completion date: February 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18

• on chronic hemodialysis treatment

Exclusion Criteria:

• All patients had a minimum of six hemoglobin measurements within a 6- month period, and they were excluded if they received a kidney transplant during this period or those who had blood transfusions during the baseline period.

• Patients with serum ferritin<100 µg/L were also excluded from the study because of reimbursement of our country.

Related Conditions & MeSH terms

• Hemodialysis-Induced Symptom

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Baskent University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Factors Influencing Hemoglobin Variability and Its Association with Mortality in Hemodialysis Patients	investigation of factors influencing hemoglobin variability with inflammatory and nutritional parameters and the association of hemoglobin variability with all-cause mortality among hemodialysis patients	six month